Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas has launched Cresemba (isavuconazonium sulfate), the prodrug for isavuconazole in the US to treat adults with invasive aspergillosis and invasive mucormycosis (zygomycosis).
Subscribe to our email newsletter
Both invasive aspergillosis and mucormycosis are life-threatening fungal infections predominantly occurring in immunocompromised patients.
In March 2015, the US Food and Drug Administration (FDA) approved a new drug application (NDA) for the use of Cresemba in patients 18 years of age and older to treat invasive aspergillosis and invasive mucormycosis.
Astellas divisional president and Global Development head Bernie Zeiher said: "The launch of Cresemba in the US marks the availability of an important new treatment option for patients and healthcare professionals fighting these life-threatening fungal infections.
"Given the high morbidity and mortality rates associated with invasive aspergillosis and invasive mucormycosis, we are excited to provide physicians and patients with this alternative therapy in an area of significant unmet medical need."
The company is jointly developing Cresemba in collaboration with Basilea Pharmaceutica International, which submitted a European marketing authorization application (MAA) in July 2014, to treat invasive aspergillosis and invasive mucormycosis in adults.